Tirzepatide
SURMOUNT-3
Eli Lilly · Phase 3 · Completed · Enrollment 579
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Tirzepatide | 114 participants | 52 participants | 89 participants | n/r | 1 |
| Placebo | 41 participants | 4 participants | 27 participants | n/r | 1 |
A count stays a count. This page does not turn a count into a percent.